Gastric Cancer, Colorectal Cancer
Conditions
Brief summary
This study is a multi-center, observational study. Participants scheduled for gastroscopy and colonoscopy will undergo an epidemiological assessment and provide a stool sample prior to endoscopy for qualitative Fecal Immunochemical Test (FIT), quantitative Fecal Immunochemical Test (FIT), and novel biomarker testing, followed by the endoscopic examination. After completion of the baseline endoscopic screening, all enrolled participants will undergo a 2-year follow-up. The primary endpoints of the study are sensitivity and specificity for the screening of gastrointestinal cancers.The aim of this study is to develop and evaluate the sensitivity and specificity of fecal multi-marker panels for the screening of gastrointestinal cancers.
Interventions
DIAGNOSTIC_TESTQualitative Fecal Immunochemical Test (FIT), quantitative (FIT), and testing for new biomarkers
Stool samples are collected from participants before endoscopy for qualitative Fecal Immunochemical Test (FIT), quantitative Fecal Immunochemical Test (FIT), and novel biomarker testing. The results are used to screen for gastrointestinal cancers.
Sponsors
Xijing Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Participants must be at least 18 years of age at the time of enrollment; 2. Participants must be scheduled to undergo gastroscopy and colonoscopy; 3. Participants must agree to undergo a two-year follow-up as outlined in the protocol; 4. Participants must be willing to participate and sign an informed consent form.
Exclusion criteria
1. Have undergone gastrointestinal endoscopy screening within the past year; 2. History of any type of gastrointestinal malignancy; 3. Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders; 4. Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short life expectancy); 5. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and Specificity of Stool-Based Biomarker Testing for Gastrointestinal Cancer Screening | At the time of baseline endoscopic screening, approximately 2 weeks after stool sample collection. |
Countries
China
Contacts
CONTACTZheng
Outcome results
None listed